Chlamydia Infection Diagnostics And Therapeutics Market Report 2026

Chlamydia Infection Diagnostics And Therapeutics Market Overview

• Chlamydia Infection Diagnostics And Therapeutics market size has reached to $1.51 billion in 2025 • Expected to grow to $1.98 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: Impact Of Rising Sexually Transmitted Diseases Incidence On Chlamydia Infection Diagnostics And Therapeutics Market • Market Trend: Advancements In Rapid Molecular Point-Of-Care Testing For Chlamydia And Other Stis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chlamydia Infection Diagnostics And Therapeutics Market?

Chlamydia infection diagnostics and therapeutics refers to the comprehensive approach to identifying and treating infections caused by the bacterium Chlamydia trachomatis. It involves the diagnostic procedures used to detect the infection and the therapeutic measures taken to treat it. The combination of chlamydia infection diagnostics and therapeutics aims to accurately detect infections, provide effective treatment, prevent complications, and reduce the spread of the disease through comprehensive and coordinated healthcare strategies. The main types of chlamydia infection diagnostics and therapeutics are nucleic acid amplification tests (NAATS), direct fluorescent tests, macrolides, quinolones, sulfonamides, tetracyclines, and aminopenicillins. Nucleic acid amplification tests (NAATS) refer to advanced diagnostic tools that detect the genetic material of Chlamydia bacteria. The different types of infections include genital chlamydia infection, rectal chlamydia infection, and ocular chlamydia infection, and the various applications include hospitals, specialty clinics, diagnostic centers, therapeutics, hospital pharmacies, drugstores, retail pharmacies, and online pharmacies.

What Is The Chlamydia Infection Diagnostics And Therapeutics Market Growth Forecast?

The chlamydia infection diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $1.98 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing adoption of advanced NAAT technologies, rising investments in sexual health programs, expansion of home-based diagnostic solutions, growing focus on antimicrobial stewardship, increasing demand for integrated diagnostic-therapeutic platforms. Major trends in the forecast period include increasing adoption of molecular diagnostic testing, rising use of rapid point-of-care diagnostics, growing preference for combination diagnostic and therapeutic approaches, expansion of antibiotic resistance monitoring, enhanced focus on early detection and screening programs.

Global Chlamydia Infection Diagnostics And Therapeutics Market Segmentation

1) By Type: Nucleic Acid Amplification Tests (NAATS), Direct Fluorescent Tests, Macrolides, Quinolones, Sulfonamides, Tetracycline, Aminopenicillins 2) By Type Of Infections: Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection 3) By Application: Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies, Drugstores, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Nucleic Acid Amplification Tests (NAATS): PCR-Based Tests, LAMP-Based Tests 2) By Direct Fluorescent Tests: Direct Fluorescent Antibody Staining, Direct Fluorescent In-Situ Hybridization 3) By Macrolides: Azithromycin, Erythromycin 4) By Quinolones: Ciprofloxacin, Ofloxacin 5) By Sulfonamides: Sulfamethoxazole, Trimethoprim-Sulfamethoxazole 6) By Tetracycline: Doxycycline, Tetracycline 7) By Aminopenicillins: Amoxicillin, Ampicillin

What Is The Driver Of The Chlamydia Infection Diagnostics And Therapeutics Market?

The rising incidence of sexually transmitted infections is expected to propel the growth of the chlamydia infection diagnostics and therapeutics market going forward. Sexually transmitted infections refer to infections typically transmitted through sexual contact, including vaginal, anal, or oral sex. The increase in sexually transmitted infections (STIs) is due to inconsistent or improper use of barrier methods, a lack of awareness and education about safe sex practices, increased travel and migration patterns, and potentially decreasing public health funding for prevention programs. Chlamydia infection diagnostics and therapeutics are essential in managing sexually transmitted infections, ensuring early detection and effective treatment to prevent complications and transmission. For instance, in October 2025, according to the Minority HIV/AIDS Fund (MHAF), an US-based government agency, an estimated in 2023, approximately 39.9 million individuals worldwide were living with HIV, consisting of 38.6 million adults and 1.4 million children, compared to previous years. Therefore, the rising incidence of sexually transmitted infections globally is driving the growth of the chlamydia infection diagnostics and therapeutics industry.

Key Players In The Global Chlamydia Infection Diagnostics And Therapeutics Market

Major companies operating in the chlamydia infection diagnostics and therapeutics market are F. Hoffman La-Roche Ltd, Merck & Co. Inc., AbbVie Inc, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca, Abbott Laboratory, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical, Danaher Corporation, Gilead Sciences, Siemens Healthineers, Becton Dickinson and Company, Accelerate Diagnostics, Hologic Inc., Biomerieux, QuidelOrtho Corporation, Bio-Rad Laboratories Inc., DiaSorin SpA, Luminex Corporation, Meridian Bioscience, Trinity Biotech Plc, Copan Diagnostics, Hain Lifescience GmbH

Global Chlamydia Infection Diagnostics And Therapeutics Market Trends and Insights

Major companies operating in the chlamydia market are focusing on developing innovative solutions such as Point-of-Care Molecular Diagnostics Expansion to enable faster, more accurate onsite detection and improve timely treatment outcomes. Point-of-care molecular diagnostics expansion refers to the broader adoption of rapid, onsite molecular tests that allow immediate detection of infections such as chlamydia without relying on centralized laboratories. For instance, in January 2025, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, received FDA 510(k) clearance along with a CLIA waiver for its cobas liat molecular tests, which are designed to diagnose sexually transmitted infections (STIs) at the point of care. These tests include multiplex assay panels that can detect and differentiate multiple STIs, such as chlamydia, gonorrhea, and Mycoplasma genitalium, from a single patient sample with results available in 20 minutes or less.

What Are Latest Mergers And Acquisitions In The Chlamydia Infection Diagnostics And Therapeutics Market?

In December 2024, OraSure Technologies, a US-based diagnostics and medical device company, acquired Sherlock Biosciences for an undisclosed amount. With this acquisition, OraSure Technologies aims to expand its molecular diagnostics portfolio, accelerate the development of rapid, point-of-care testing solutions, and enhance its capabilities in innovative infectious disease detection. Sherlock Biosciences is a US-based biotechnology company that develops CRISPR-based diagnostic tools for infectious diseases.

Regional Outlook

North America was the largest region in the chlamydia infection diagnostics and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chlamydia Infection Diagnostics And Therapeutics Market?

The chlamydia infection diagnostics and therapeutics market consists of revenues earned by entities providing services such as swab testing, molecular testing, serological tests, urine testing, direct fluorescent antibody (DFA) testing, and enzyme-linked immunosorbent assays (ELISA). The market value includes the value of related goods sold by the service provider or included within the service offering. The chlamydia infection diagnostics and therapeutics market also includes sales of nucleic acid amplification tests (NAAT) kits, chlamydia culture kits, enzyme-linked immunosorbent assay (ELISA) kits, polymerase chain reaction (PCR) kits, and antibiotics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chlamydia Infection Diagnostics And Therapeutics Market Report 2026?

The chlamydia infection diagnostics and therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia infection diagnostics and therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.